Currency In USD
| Previous Close | 0.65 |
| Open | 0.71 |
| Day High | 0.9 |
| Day Low | 0.69 |
| 52-Week High | 52.95 |
| 52-Week Low | 0.52 |
| Volume | 5.96M |
| Average Volume | 3.68M |
| Market Cap | 4.92M |
| PE | -0.03 |
| EPS | -24.24 |
| Moving Average 50 Days | 1.12 |
| Moving Average 200 Days | 6.94 |
| Change | 0.19 |
Data not available
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
GlobeNewswire Inc.
Jan 07, 2026 1:45 PM GMT
Trading under DCOY to commence on January 8, 2026 Company’s proprietary peptide-conjugate platform leverages AI-enabled computational infrastructure to accelerate candidate selection Capital-efficient 2026 plan features advancing lead antiviral into
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
GlobeNewswire Inc.
Dec 19, 2025 4:12 PM GMT
HOUSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (“Salarius” or the “Company”) today announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for and convened on December 19, 20
Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform
GlobeNewswire Inc.
Dec 18, 2025 12:50 PM GMT
The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker “DCOY” effective in early January 2026 Company to focus on advancing lead antiviral programs, expanding platform validation and a